Zymeworks Inc. (ZYME)

Zymeworks' stock has gained over 46% in the past six months. In October 2025, H.C. Wainwright reiterated a "Buy" rating with a $26.00 price target, and Wells Fargo initiated coverage with an "Equal Weight" rating, raising its price target from $14.00 to $15.00 after promising Phase 1 results for ZW191 and the appointment of Adam Schayowitz as Acting Chief Development Officer. In September 2025, Zymeworks discontinued its ZW171 cancer drug development due to an unfavorable benefit-risk profile. In August 2025, Zymeworks reported second-quarter 2025 financial results with $48.7 million in revenue and projected a cash runway into the second half of 2027. Analysts have issued a consensus rating of "Buy" with an average 1-year target price of $24.75.

As a clinical-stage biopharmaceutical company, Zymeworks Inc. does not experience traditional demand seasonality for its products and services. The demand for its product candidates is driven by ongoing medical need, the progression of clinical trials, regulatory approvals, and commercialization efforts, rather than seasonal consumer trends. While there might be some general stock market seasonality, this does not reflect seasonality in the demand for the company's biotherapeutic products.

Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel, multifunctional biotherapeutics for difficult-to-treat diseases like cancer, inflammation, and autoimmune conditions. The company's business centers on its therapeutic platforms and drug development engine, enabling the engineering of differentiated therapeutic product candidates. Zanidatamab, a HER2-targeted bispecific antibody, is undergoing multiple clinical trials globally and has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for previously treated, unresectable or metastatic HER2-positive biliary tract cancer. ZW191, an antibody-drug conjugate targeting folate receptor-alpha, has shown promising anti-tumor activity in advanced solid tumors, including gynecological cancers, with a 64% objective response rate at higher doses in gynecological cancer patients. The U.S. FDA cleared the IND application for ZW251, with first-in-human studies planned for 2025.

Zymeworks Inc. is headquartered in Vancouver, British Columbia, Canada. Zanidatamab, the company's lead product, has a global reach with regulatory approvals in the United States, China, and Europe.

Zymeworks' brand reputation in the past year is largely positive, driven by promising clinical trial results and positive analyst sentiment. The encouraging Phase 1 data for ZW191 has been highlighted by analysts and news outlets. Strategic appointments and advancements in its pipeline also contribute to a favorable perception. The discontinuation of the ZW171 cancer drug development was framed as a strategic decision, and the overall focus remains on a promising pipeline. Analyst sentiment remains positive, with a consensus "Buy" rating.

Approximately 64.0% of Zymeworks Inc.'s shares are held by institutional investors, including EcoR1 Capital, LLC, Rubric Capital Management LP, Bvf Inc/il, Morgan Stanley, Redmile Group, LLC, BlackRock, Inc., Vanguard Group Inc, UBS Asset Management Americas Inc, BNP Paribas Asset Management Holding S.A., and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Insiders hold approximately 31.38% of the company's stock, with Oleg Nodelman and EcoR1 Capital LLC being significant shareholders. Insider activity has shown a positive trend with purchases over the past 12 months.